Our work on arginine methylation via PRMT6 in mediating liver cancer stemness is published in this week’s issue of Cell Reports. Read all about it!

Chan LH*, Zhou L*, Ng KY*, Wong TL*, Lee TK, Sharma R, Loong JH, Ching YP, Yuan YF, Xie D, Lo CM, Man K, Artegiani B, Clevers H, Yan HH, Leung SY, Richard S, Guan XY, Huen MS, Ma S. PRMT6 regulates RAS/RAF binding and MEK/ERK-mediated cancer stemness activities in hepatocellular carcinoma through CRAF methylation. Cell Rep 2018; 25:690-701. (*equal contribution)

https://www.cell.com/cell-reports/fulltext/S2211-1247(18)31498-0

Our work on the role of ANXA3 in sorafenib resistance is now published in the Journal of Hepatology. Congrats to Carol and the team!

Tong M, Che N, Zhou L, Luk ST, Kau PW, Chai S, Ngan ES, Lo CM, Man K, Ding J, Lee TK, Ma S. Efficacy of antibody-mediated annexin A3 blockade in sensitizing hepatocellular carcinoma to sorafenib and regorafenib treatment. J Hepatol 2018; Epub ahead of print.

https://www.journal-of-hepatology.eu/article/S0168-8278(18)32119-6/fulltext

Our work on the role of FSTL1 in promoting metastasis and chemoresistance in ESCC via NFkB-BMP signaling crosstalk published in the November 2017 issue of Cancer Research. Congratulations to Marco, Johnson and the team!

http://cancerres.aacrjournals.org/content/early/2017/09/07/0008-5472.CAN-17-1411

Our work on the role of TP53INP1 in HCC metastasis published in the September 2017 issue of Cancer Research. Congratulations to Johnson!

http://cancerres.aacrjournals.org/content/77/17/4602